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The role of phospholipid as a solubility- and permeability-enhancing excipient for
the improved delivery of the bioactive phytoconstituents of Bacopa monnieri
Abstract
In an attempt to improve the solubility and permeability of Standardized Bacopa Extract (SBE), a
complexation approach based on phospholipid was employed. A solvent evaporation method was used to
prepare the SBE-phospholipid complex (Bacopa Naturosome, BN). The formulation and process variables
were optimized using a central-composite design. The formation of BN was confirmed by
photomicroscopy, Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FTIR),
Differential Scanning Calorimetry (DSC), and Powder X-ray Diffraction (PXRD). The saturation solubility,
the in-vitro dissolution, and the ex-vivo permeability studies were used for the functional evaluation of the
prepared complex. BN exhibited a significantly higher aqueous solubility compared to the pure SBE
(20-fold), or the physical mixture of SBE and the phospholipid (13-fold). Similarly, the in-vitro dissolution
revealed a significantly higher efficiency of the prepared complex (BN) in releasing the SBE (> 97%) in
comparison to the pure SCE (~ 42%), or the physical mixture (~ 47%). The ex-vivo permeation studies
showed that the prepared BN significantly improved the permeation of SBE (> 90%), compared to the pure
SBE (~ 21%), or the physical mixture (~ 24%). Drug-phospholipid complexation may thus be a promising
strategy for solubility enhancement of bioactive phytoconstituents.
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Abstract
In an attempt to improve the solubility and permeability of Standardized Bacopa Extract (SBE),
a complexation approach based on phospholipid was employed. A solvent evaporation method

PT

was used to prepare the SBE-phospholipid complex (Bacopa Naturosome, BN). The formulation
and process variables were optimized using a central-composite design. The formation of BN

RI

was confirmed by photomicroscopy, scanning electron microscopy (SEM), Fourier transform

SC

infrared spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and Powder X-ray
Diffraction (PXRD). The saturation solubility, the in-vitro dissolution, and the ex-vivo
permeability studies were used for the functional evaluation of the prepared complex. BN

NU

exhibited a significantly higher aqueous solubility compared to the pure SBE (20-fold), or the
physical mixture of SBE and the phospholipid (13-fold). Similarly, the in-vitro dissolution

MA

revealed a significantly higher efficiency of the prepared complex (BN) in releasing the SBE
(>97 %) in comparison to the pure SCE (~42 %), or the physical mixture (~47 %). The ex-vivo

D

permeation studies showed that the prepared BN significantly improved the permeation of SBE

TE

(>90 %), compared to the pure SBE (~21 %), or the physical mixture (~24 %). Drugphospholipid complexation may thus be a promising strategy for solubility enhancement of
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P

bioactive phytoconstituents.

Keywords
Excipients, Phytoconstituents, Complexation, Solubility, Permeability

ACCEPTED MANUSCRIPT
Introduction
Recent years have seen a dramatic increase in the popularity of natural products in the
management of several ailments (Sikarwar et al., 2008). Among other challenges, the poor

PT

bioavailability of the bioactive phytoconstituents is accepted as a major limitation to the use of
natural products in mainstream pharmacotherapy. Attributes such as high molecular size, poor

RI

aqueous solubility, and lower plasma membrane permeability of pharmacologically active

SC

phytoconstituents are known to result in overall poor bioavailability of these components, thus
limiting their pharmaceutical applications (Husch et al., 2013; Manach et al., 2004).
A major rate-limiting factor in the development of pharmaceutical drug products from the

NU

bioactive phytoconstituents is improving their solubility and permeability, thereby optimizing
their bioavailability. Preparing drug-phospholipid complexes is among the several recently

MA

explored, and promising approaches aimed at improving the bioavailability of drugs. Several
studies have reported an improvement in the solubility, permeability, and subsequently the

D

systemic absorption and bioavailability of active phytoconstituents by forming their aggregates

TE

with phospholipid molecules (forming Naturosomes, Phytosomes, or Herbosomes) (Husch et al.,
2013; Khan et al., 2013). The pharmacological profiles have also been shown to successfully
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improve by using drug-phospholipid complexation approaches (Freag et al., 2013; Kennedy et
al., 2007; Mukherjee et al., 2011; Pathan and Bhandari, 2011; Zaidi et al., 2011). Additionally,
fundamental advantages and significant breakthroughs for clinical use have been observed for
several phytoconstituents by improving their oral availability, owing to the amphiphilic
characteristics of Naturosomes (Fricker et al., 2010; Kidd, 2009). Naturosome technology have
been successfully used to deliver herbal extracts as well as phytochemicals with significant
improvements in pharmacokinetic as well as in pharmacodynamic functionalities (Kennedy et
al., 2007; Kidd and Head, 2005; Maiti et al., 2006; Maiti et al., 2009).
Bacopa monnieri Linnis a plant native to the Indian subcontinent, and has been described
in ancient text as being used to sharpen intellect and attenuate several mental deficits (Aguiar
and Borowski, 2013; Sairam et al., 2002). Current literature also reports its usefulness in the
treatment of anxiety, improving cognitive functions, memory enhancement, neuroprotection, and
hepato-protection (Calabrese et al., 2008; Janani et al., 2009; Rastogi et al., 2012). The major
pharmacologically active constituents reported in Bacopa monnieri are bacopasides (triterpenoid
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saponins) such as bacoside A3, bacopaside I, bacopaside II, bacoside A (bacopasaponine C), and
a jujubogenin isomer of bacopasaponine C (Sivaramakrishna et al., 2005; Zhou et al., 2007).
Safety, efficacy, and quality are the cornerstones of any pharmaceutical product

PT

application. In recent years, the goal of developing a quality product, and minimizing its
functional variability have been successfully achieved via adopting a Quality by Design (QbD)

RI

principles. QbD has been described earlier as a scientific, risk-based, holistic, and proactive

SC

approach to pharmaceutical development (Dave et al., 2015). This approach includes a sound
science-based understanding of the predefined objectives, formulation and process variables, and

NU

a thorough assessment and management of risks with respect to the product quality.
Several pharmaceutical and nutraceutical products containing extracts of Bacopa

MA

monnieri are commercially available (Pravina et al., 2007). However, the current literature lacks
studies on the issue of the low aqueous solubility of its extract, and any approaches to improve
the solubility. In a recent study, the authors have demonstrated success in improving the

D

solubility and permeability of a standardized extract of Centella asiatica via preparation of its

TE

complex with a hydrogenated soy phosphatidylcholine (Phospholipon® 90H)(Saoji et al., 2015a).
In the present study, this approach was used to assess the feasibility of improving the aqueous
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solubility of Standardized Bacopa Extract (SBE).
The primary objective of this study was to prepare and optimize the SBE-Phospholipon®
90H complex by a modified solvent evaporation method. The formulation and process variables
were optimized by the means of a central composite design. The prepared complex was
characterized for its physicochemical properties using photo microscopy, Scanning Electron
Microscopy (SEM), particle size distribution and zeta potential, Fourier Transform Infrared
Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis
(TGA), and Powder X-Ray Diffractometry (PXRD). The functional properties of the prepared
complex were evaluated by saturation solubility studies, in-vitro dissolution studies, and ex-vivo
permeation studies. These properties of the prepared complex were compared to that of the pure
SBE and a physical mixture (1:1) of SBE and Phospholipon® 90H.
Materials and methods
Materials
The Standardized Bacopa Extract (SBE), containing approximately 40% w/w bacopasides was
obtained from Arjuna Natural Extracts Ltd, Kerala, India. The identity and purity of the SBE
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composition were confirmed by HPLC analysis. The hydrogenated soy phosphatidylcholine i.e.
Phospholipon® 90H obtained from Lipoid, Ludwigshafen, Germany. All other chemicals and
reagents used were of analytical grade.

PT

Analytical method for the triterpenes present in SBE

The concentrations of the triterpene saponins present in SBE i.e. bacoside A (a mixture of

RI

bacoside A3, bacopaside II, jujubogenin isomer of bacopasaponine C, and bacopasaponine C)

SC

were determined using a modified, reverse-phase high performance liquid chromatography (RPHPLC) method previously described by Phrompittayarat et al. (Phrompittayarat et al., 2007).

NU

Briefly, the HPLC system (Model: Prominence, Shimadzu Corporation, Kyoto, Japan) with LC
solution software, equipped with a LC-20AD HPLC pump, a manual rheodyne sample injector,

MA

and a SPD-M20A detector were utilized for the separation. The mobile phase composed of
phosphoric acid (0.2%): acetonitrile (65:35 v/v), pH adjusted to 2.8 with 3M Sodium hydroxide,
and a flow rate of 1.5 mL/min. A Micra- NPS RP18 column (33×8.0×4.6 mm, 1.5μm) was used

D

as a stationary phase, and the detector wavelength was 205 nm at room temperature. The

TE

trailing/asymmetry factor, theoretical plates, and the relative standard deviation (RSD) were
calculated to monitor the system suitability of the chromatographic setup. The calibration curves
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were obtained by plotting the peak areas versus concentration of the standard solution. For each
component of the extract (bacopaside), seven concentrations of standard solution were analyzed.
The implemented chromatographic method was validated by analyzing several relevant
validation characteristics such as linearity, accuracy, and precision.
Preparation of Bacopa Naturosome (BN)
A slightly modified solvent evaporation method, previously described by Bhattacharyya et al.
was used to prepare the BN (Bhattacharyya et al., 2014a). Briefly, different ratios of
Phospholipon® 90H and SBE, i.e. 0.5:1, 1:1, 1.75:1, 2.5:1, or 3:1 were added to a 100 mL round
bottom flask containing 40 mL ethanol. The reactions were carried out at various controlled
temperatures, i.e. 40°C, 44°C, 50°C, 56°C, or 60°C, and for different durations, i.e. 1h, 1.4h, 2h,
2.6h or 3 h.The resultant clear solution was evaporated to about 2-3 mL. Excess amount of nhexane was added to this mixture with continuous stirring. The formed BN was then precipitated,
filtered, and dried under a vacuum to remove any traces of the solvents. The prepared BN was
stored at room temperature in amber colored bottles, flushed with nitrogen.
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Quality by Design (QbD) based design of experiments
The Critical Quality Attributes (CQA) of the product, i.e. the drug entrapment efficiency of the
BN was studied systematically for the joint influence of the formulation and the process

PT

variables such as, phospholipid-to-drug ratio (X1, w:w), reaction temperature (X2, °C), and the
reaction time (X3, h) by applying a QbD-based approach using central composite design. Using

RI

this design, 20 possible combinations of experimental trials were carried out to analyze the

SC

influence of the above three factors (Yue et al., 2010; Yue et al., 2008). The responses were
evaluated employing a statistical model incorporating the interactive and polynomial terms using
the equation I below:

NU

𝑌 = 𝑏0 + 𝑏1 𝑋1 + 𝑏2 𝑋2 + 𝑏3 𝑋3 + 𝑏11 𝑋12 + 𝑏22 𝑋22 + 𝑏33 𝑋32 + 𝑏12 𝑋1 𝑋2 + 𝑏23 𝑋2 𝑋3 + 𝑏13 𝑋1 𝑋3 (I)

Where, 𝑌 is the dependent variable, 𝑏0 is the arithmetic mean response of the 20 runs, and 𝑏𝑖 is

MA

the estimated coefficient for the factor 𝑋𝑖 . The average response due to a change in the level of
one factor at a time is represented by the main effects (𝑋1 , 𝑋2 , and 𝑋3 ). The changes in the
response when all factors were simultaneously changed are represented by the interaction terms

D

(𝑋1 𝑋2 , 𝑋2 𝑋3 , and 𝑋1 𝑋3 ). The on-linearity was evaluated by including the polynomial terms (𝑋12 ,
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the trial batches, respectively.

TE

𝑋22 , and 𝑋32 ). The tables, 1 and 2 shows the levels of the evaluated factors, and the composition of

Entrapment efficiency of BN
The entrapment efficiency, i.e. the total bacopaside content entrapped in the prepared BN was
analyzed using a combination of methods previously described in the literature (Bhattacharyya et
al., 2013; Tan et al., 2012). Briefly, ~100 mg of BN was dispersed in 10 mL chloroform. The
prepared BN and any unused Phospholipon® 90H both were easily dissolved in the chloroform.
The non-entrapped SBE (free bacopasides) in the mixture was insoluble, and collected as a
sediment. This non-entrapped SBE was then separated via filtration and assayedusing the HPLC
procedure described above.The entrapment efficiency of BN was calculated using the equation
(II) below:
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =

𝐶𝑡 − 𝐶𝑓
× 100
𝐶𝑡

(II)

Where, 𝐶𝑡 = Total concentration of SBE, and 𝐶𝑓 = SBE contained in the filtrate.
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Determination of SBE content in BN
The SBE content in the prepared BN was determined by HPLC method described above. The
drug content was calculated using equation (III) below, previously described by Bhattacharya et
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝐶𝑁
× 100
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝑁

(III)

RI

𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (%) =

PT

al.(Bhattacharyya et al., 2014b).

SC

Physico-chemical characterization of CN
Photomicroscopy
The prepared BN was morphologically characterized using photomicroscopy. Briefly, a

NU

suspension containing approximately 100 mg of the prepared BN powder was transferred to a
glass tube and diluted with 10 mL Phosphate Buffer Saline (PBS, pH 7.4). The suspended

MA

dispersion was then mounted on a clear glass slide, and photomicrographs were recorded using
an optical microscope equipped with a camera (Model: DM 2500, Leica Microsystems,
Germany) at 20x magnification.

TE

D

Scanning Electron Microscopy (SEM)
The prepared BN was also evaluated by SEM to characterize the surface morphology. Briefly,
the BN powder obtained from the optimized formulation batches was sprinkled on a double-
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sided carbon tape, and the tape was placed on a brass stub. The auto fine coater (Model:
JFC1600, Jeol Ltd., Tokyo, Japan) was used to coat the powder surface with a thin layer of
palladium. The SEM photomicrographs of the palladium coated samples were obtained on a
Scanning Electron Microscope (Model: JSM-6390LV, Jeol Ltd, Tokyo, Japan) operating at 10
KV accelerating voltage,and equipped with a digital camera.
Particle size and zeta potential analysis
The prepared BN was analyzed for particle size distribution and zeta potential with dynamic light
scattering on a nanoparticle analyzer (Model: nano Partica SZ-100, Horiba Instruments, Irvine,
CA) equipped with a Helium-Neon laser (5mW),with a wavelength output of 633 nm. The
samples were measured at an angle of 90°, at 25 °C. Water was used as a dispersant, and the
sample run-time was at least 40-80 seconds. The zeta potential was calculated using the
Smoluchowski’s equation from the electrophoretic mobility of naturosomes(Sze et al., 2003). All
measurements were carried out in triplicate.
Fourier Transform Infrared (FTIR) Spectroscopy
An FTIR spectrophotometer (Model: IR Prestige-21, Shimadzu, Japan) equipped with an
attenuated total reflectance (ATR) accessory was used to record the infrared spectra of pure SBE,
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Phospholipon® 90H, the physical mixture of SBE with Phospholipon® 90H(PM), and the
prepared BN. The samples were analyzed in a diffuse reflectance modeusing KBr pellets. In
order to remove any influence of the residual moisture present in the sample on the quality of the

PT

spectra, all samples were subjected to vacuum drying prior to sample analysis. The spectrafor all
samples were obtained in the wavelength region of 4000 to 400 cm−1 (Dhore et al., 2016).

RI

Thermal analysis
Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA) techniques

SC

were used to analyze the thermal behavior of SBE, Phospholipon® 90H, the physical mixture

NU

(50:50) of SBE and Phospholipon® 90H (PM), and the prepared BN. A differential scanning
calorimeter (Model: Q20, TA Instruments, Inc., New Castle, DE, USA) was used to determine
and compare the peak-transition/peak-onset temperatures of the tested samples. The analysis was

MA

carried out under a purge of dry nitrogen gas (50 mL/min). The instrument was calibrated for the
heat flow and the heat capacity using a high-purity indium standard. Accurately weighed, 5

D

mgsamples were hermetically sealed in aluminum cells using a crimper. The samples were

2015b).

TE

subjected to a single heating cycle from 0°C to 400°C at a heating rate of 10°C/min (Saoji et al.,
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The thermogravimetric analysis of samples, i.e. SBE, Phospholipon® 90H, PM and BN,
were carried out using a thermogravimetric analyzer (Model: TGA Q50, TA Instruments, Inc.,
New Castle, DE, USA). TGA analysis was carried with a nitrogen flow rate of 60 mL/min
through the furnace. Accurately weighed samples(~5 mg) were subjected to a single heating
cycle from 0°C to 400°C at a heating rate of 10°C/min.The data obtained from the thermal
analysis of the samples were analyzed using the software (Universal Analysis, V.4.5A, build
4.5.0.5, TA Instruments, Inc., New Castle, DE, USA).
Powder x-ray diffraction (PXRD)
Apowder x-ray diffractometer (Model: D2 Phaser, Bruker AXS, Inc., Madison, WI, USA)
equipped with a Bragg-Brentano geometry (θ/2θ) optical setup was used to determine the
polymorphic state of the tested samples, i.e. SBE, Phospholipon® 90H, PM and BN. A Bruker
AXS’ compound silicon strip technology based LYNXEYETM detector was used to monitor the
diffraction pattern of the samples. An operating voltage and amperage of 30 mV and 10 mA
respectively, was maintained for proper functioning of monochromatic CuKβ radiation
(λ=1.5406 A°). The diffraction patterns of samples were recorded at a step-angle of 0.2º 2θ with
the diffraction angle increasing from 2º to 90º and a count time of 0.5 seconds.
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Functional evaluation of CN
Apparent solubility analysis
The apparent solubility of pure SBE and the SBE incorporated in the prepared BN were analyzed

PT

and compared using the method previously described by Singh et al. (Singh et al., 2013). Briefly,
excess of pure SBE or BN were placed in sealed glass containers containing 10 mL of water or

RI

n-Octanol. The dispersion was continuously agitated 25ºC for 24 hours. The dispersion was then
centrifuged for 30 min at 4000 RPM. The supernatant was collected and filtered through a

SC

membrane filter (0.45µ) to remove any insoluble particulate matter. Appropriate dilutions were
prepared by mixing this filtrate with the mobile phase. These samples were then measured for

NU

SBE concentration at an absorbance wavelength of 205 nm, using the RP-HPLC method
described above.

MA

In-vitro drug release (dissolution)
The release profiles of pure SBE and the prepared BN were determined and compared with the
in-vitro dissolution study, using the method previously described by Zhang et al. (Zhang et al.,

D

2014). Briefly, the study was carried out using a six-station dissolution test apparatus, type II

TE

(Model: TDT-06T, Electrolab India Pvt. Ltd., India), and the dissolution medium consisted of
900 mL phosphate buffer (pH-6.8), maintained at 37ºC ± 0.5ºC. Accurately weighed samples of

AC
CE
P

pure SBE (50 mg) or the prepared BN (≈50 mg SBE) were placed on the surface of the medium.
The dissolution was carried out at 100 RPM, for a period of 11 hours. Samples (10 mL) were
withdrawn at hourly intervals, and the dissolution vessels were replenished with an equal volume
of fresh medium to maintain the sink conditions. The withdrawn samples were filtered through a
membrane filter (0.45 µm), diluted appropriately with the mobile phase, and analyzed using the
RP-HPLC method described above.
Dissolution efficiency (DE)
The dissolution behavior of pure SBE and the prepared BN was further analyzed by calculating
and comparing their dissolution efficiencies (DE) at the end of 11 hours. Anderson et al.
previously described a method for comparing the dissolution profiles of molecules based on the
differences in the areas under the dissolution curve between any given time points. The
dissolution efficiencies for the tested samples were calculated using the equation (IV) below.
𝑡

𝐷𝐸 =

2
∫𝑡 𝑦. 𝑑𝑡
1

𝑦100 × (𝑡2 − 𝑡1 )

× 100

(IV)
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Where, 𝑦 is the percentage of dissolved drug. 𝐷𝐸 is the area under the dissolution curve between
time points 𝑡1 and 𝑡2 expressed as a percentage of the curve at maximum dissolution,𝑦100 ,
overthe same time period.The area under the dissolution curve was calculated using amodel

𝐴𝑈𝐶 = ∑
𝑖=1

(𝑡1 − 𝑡𝑖−1 )(𝑦𝑖−1 + 𝑦𝑖 )
(V)
2

RI

𝑖=𝑛

PT

independent trapezoidal methodby employingthe equation (V) below.

Where 𝑡𝑖 is the i time point, 𝑦𝑖 is the percentage of dissolved drug at time 𝑡𝑖.

SC

th

NU

Ex-vivo permeability
An apparatus based on everted rat intestine, previously described by Dixit et al. was employed
for the evaluation of ex-vivo permeability of the SBE (Dixit et al., 2012). The apparatus

MA

consisted of two glass tubes held together by a joint with the open, tapering ends facing each
other. An inbuilt bulge at the end of each tube facilitated the mounting of the tissue. The
apparatus was designed to be conveniently set up in a 250 mL glass beaker. The entire assembly

D

was placed in a glass beaker after mounting the everted rat intestinal segment. The interior of the

TE

glass tubes served as the receiver compartment, whereas the space between the apparatus
assembly and the beaker served as the donor compartment.
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Prior approvals were obtained from the Institutional Animal Ethics Committee (IAEC)
for the handling and use of the experimental animals in the study. Overnight fasted SpragueDawley® rats (200-250 g) were euthanized by cervical dislocation. The abdomen was exposed by
giving a midline incision, and the ileo-cecal junction was identified after carefully maneuvering
the intestine. A section of the intestine (jejunum, ~7 cm) was isolated from the mesenteric
attachments carefully without damaging the intestine. The isolated segment was thoroughly
washed with Krebs solution, and everted using a glass rod. The everted segment was transferred
to a petri dish containing fresh Kreb’s solution. For the permeability experiments, a 6 cm
segment was used.
The everted piece of intestine was mounted between the two tapered ends of the
perfusion apparatus. The perfusion apparatus was filled with Krebs solution and placed in the
glass beaker (250 mL) containing SBE, PM, or BN (≈100 μg/mL SBE) in 250 mL Krebs
solution. The whole assembly was placed on a constant temperature (37 °C ± 2°C) magnetic
stirrer, and the contents stirred at 25 RPM. The Krebs solution was continuously aerated with
carbogen (Oxygen: Carbon dioxide (95:5) mixture). The samples from within the apparatus were
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collected at 15 min intervals up to three hours and analyzed by the RP-HPLC to estimate the
permeability.

PT

Preliminary pharmacological evaluation
Animals: Male Swiss albino mice (4 months old) were housed in groups of 6 mice/cage under
controlled room temperature (25 ± 2 °C), relative humidity (50- 70% RH), and maintained under

RI

natural light/dark cycle. Food (Trimurti feeds, Nagpur, India) and water was given ad libitum,

SC

except during experimentation. All experiments were conducted during between 9:00 AM and
3.00 PM. All experimental procedures and protocols were carried out under strict ethical

NU

guidelines, and were duly approved by Institutional Animal Ethics Committee, Department of
Pharmaceutical Sciences, R. T. M. Nagpur University, Nagpur, Maharashtra, India.
Tail Suspension Test: The potential antidepressant effects of pure SBE and the prepared SBE-
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Phospholipid complex (BN) were evaluated using the ‘Tail Suspension Test’ described earlier by
Steru et al., with some modifications(Steru et al., 1985). The doses used in this study were

D

similar to those reported to be effective in the animals (Sairam et al., 2002). The animals were

TE

administered saline (control), imipramine (10 mg/kg, intraperitoneal), pure SBE (40 mg/kg), or
the prepared SBE-Phospholipid complex (equivalent to 40 mg/kg) orally, for a period of five
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days. The animals were then suspended from their tails, 50 cm above the floor, by using an
adhesive tape placed at 1 cm from the tip of the tail. The animals were left suspended for 6
minutes and the immobility was observed for the final 4 minutes. The animals were considered
immobile if they remained suspended passively without any body movements. This procedure
was repeated for five days. On the fifth day, the animals were observed for immobility 30
minutes after the administration of the test material (blank, standard, or the drug) (Sairam et al.,
2002).
Forced Swim Test: The antidepressant effects of pure SBE and the prepared SBE-Phospholipid
complex (BN) were additionally evaluated using the ‘Forced Swim Test’ in mice, another welldocumented method commonly utilized for evaluating the antidepressant effect of drugs (Porsolt
et al., 1977). The doses used in this study were similar to those reported to be effective in the
animals (Sairam et al., 2002). The animals were administered saline (control), imipramine (10
mg/kg, intraperitoneal), pure SBE (40 mg/kg), or the prepared SBE-Phospholipid complex
(equivalent to 40 mg/kg) orally, for a period of five days. The animals were individually forced
to swim in a cylindrical glass tank (20 cm in diameter × 25 cm tall) containing water at a height
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of 10 cm, maintained at 25 ± 2 °C, for the period of 6 min. While excluding the initial 2 minutes
of observed vigorous activity, the immobility time was evaluated for the final 4 minutes. The
animals were considered immobile if they floated passively in water, making only necessary

PT

movements to keep their heads above the water level. This procedure was repeated for five days.
On the fifth day, the animals were observed for immobility 30 minutes after the administration of

RI

the test material (blank, standard, or the drug) (Sairam et al., 2002). A decrease in the duration of

SC

immobility was considered as an indication of the pharmacological effectiveness of the
treatment.
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Statistical analysis
The statistical analysis of the behavioral data from theTail Suspension Test and Forced Swim
Test was carried out by one-way analysis of variance (ANOVA), followed by post hoc

considered to be significant at p < 0.05.

MA

Bonferroni’s multiple comparison test. The data are presented as mean ± SEM. The results were
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Results and discussion
Preparation of Bacopa Naturosome (BN)
A preliminary investigation of the studied process parameters revealed that the factors
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phospholipid-to-drug ratio, reaction temperature, and the reaction time highly influenced
entrapment efficiency of the prepared naturosomes. The results of the entrapment efficiency (%
w/w) are shown in Table 2. The measured values from the experimental trials revealed a wide
range (~53 - 88, % w/w) of entrapment efficiencies in the prepared BN. The fitted polynomial
equations relating the response (entrapment efficiency, % w/w) to the transformed factors are
shown in Figure 1. The polynomial equations could be used to draw conclusions after
considering the magnitude of coefficient and the mathematical sign it carries, i.e., positive or
negative. The results from the Figure 1 indicated that the coefficientsb1, b2, b3, b11, b12, b13, b22,
b23, and b33 were statistically significant (p < 0.05). The value of correlation coefficient (R2) was
observed to be 0.9457, indicating a good fit to the quadratic model. The multiple regression
analysis also revealed that the coefficientsb1, b2, and b3were positive. These results indicated that
the entrapment efficiency of the prepared BN increased with increasing levels of X1, X2, and X3.
The analysis shown in the Table 3 further indicated that the quadratic model was statistically
significant (Fcritical value = 19.38; p <0.001).
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The data from all the 20 batches of central composite design were used for generating
interpolated values using Design-Expert® (V9, Stat-Ease, Inc., Minneapolis, MN). Based on the
employed central composite design, the changes in the entrapment efficiencies (% w/w) as a

PT

function of varying levels ofX1, X2, and X3 are exhibited in the form of response surface, and
contour plots in Figure 2. The response surface and contour plots also indicated a strong

RI

influence of the studied factors X1, X2, and X3 on the entrapment efficiencies of the prepared BN.
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In general, the higher levels of X1, X2, and X3 were observed to be favorable conditions for
optimizing the entrapment efficiency. Thus, based on the multiple regression model and the
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above observations, the optimal set of conditions for the preparation of BN were found to be 3:1,
60°C, and 3 hours for the phospholipid: drug ratio, the reaction temperature, and the reaction

MA

time, respectively.

Validation of the model
The robustness of the developed model were evaluated by preparing an additional batch of BN,

D

using the model-optimized formulation and processing conditions. This new batch was prepared
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using a phospholipid: drug ratio of 3:1, the reaction temperature of 60°C, and a reaction time of 3
hours. The table 4 shows the values of the entrapment efficiency of the prepared BN as predicted
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by the model, as well as that achieved from the prepared validation batch. The entrapment
efficiency for the batches of BN prepared under the optimized conditions was found to be 87.09
%. These results were found to be comparable to the model-predicted value, i.e. 85.67 %,
indicating the validity and the robustness of the developed model. The calculated bias (%) based
on the equation VI below, was found to be -1.65%, further supporting the robustness of the
model (Qin et al., 2010).

𝐵𝑖𝑎𝑠 (%) =

𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 − 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
× 100
𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒

(VI)

Physico-chemical characterization of the prepared CN
Photomicroscopy and Scanning electron microscopy (SEM)
Figures 3 and 4 shows the surface morphological characteristics of the SBE or the prepared BN,
as observed by photomicroscopy (Figure 3) and scanning electron microscopy (Figure 4). The
surface morphologies of the SBE and the prepared BN are compared at 20x magnification in the
figure 3. The SBE particles were exhibited as thin, mostly transparent, needle-shaped crystals
(Fig. 3A). The particles of the prepared BN appeared to be larger, opaque, irregularly-shaped,
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and non-crystalline with a porous surface (Fig. 3B). The SBE particles appeared to be either
entrapped, or partially amorphized in the prepared BN.
Further analysis of the surface morphology of the prepared BN by SEM is shown in the

PT

Figure 4 (A, B, and C). The electron micrographs at different magnifications i.e. 1000x (4A),
3000x (4B), and 6000x (4C) revealed that the BN particles were composed of irregular sized and

RI

shaped vesicles of Phospholipon® 90H, with the SBE particles possibly intercalated within the

SC

lipid layers.
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Particle size and zeta potential analysis
The figure 5 shows the particle size distribution and the zeta potential values of the prepared BN.
From the analysis, the mean particle size of the BN prepared using the optimized conditions was
found to be 395 nM ± 11nM. There exists an inverse relationship between the surface

MA

area/volume (SA/V) and the particle size of most pharmaceutical particles. Thus, the release of
the entrapped drug is greatly facilitated due to the smaller particle size of the BN. Additionally,

D

the smaller size of the BN also facilitates their penetration into, and permeation through most
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physiological barriers. It has been previously suggested that particles larger than 5 mm are
typically taken up via the lymphatic system, while particles smaller than 500 nm typically
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traverse biological membranes via endocytosis (LeFevre et al., 1978; Savic et al., 2003).
Another parameter commonly used to assess the physical stability of the naturosomes is
the zeta potential. For the prepared BN, the observed zeta potential value was found to be -37.6 ±
1.1 mV. These results are in accordance with previously published results stating that the zeta
potential values higher than -30 mV are acceptable, and indicative of good physical stability
(Freitas and Müller, 1998).

Fourier transform infrared Spectroscopy (FTIR)
The figure 6 (A-D) shows the FTIR spectra of pure SBE (Fig. 6A), Phospholipon® 90H (Fig.
6B), the physical mixture of SBE with Phospholipon® 90H (Fig. 6C), and the prepared BN (Fig.
6D). The spectrum of pure SBE showed alkyl stretching peaks at ~2944 cm-1 and ~2882 cm-1. A
bending peak was also observed at ~1446cm-1. The ketone functional groups present in the SBE
were represented by a moderate peak at ~1717 cm-1. The aromatic nature of the basic ring
nucleus of the triterpenes present in the SBE was represented as the aromatic stretching peak in
the region of ~1514 cm-1. The aromatic nucleus also contained a side chain with an alkene
carbon, and represented by a broad stretching peak around 3309 cm-1. The C-O bonds
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corresponding to the furanosyl and pyranosyl group in the ring are exhibited by the peaks around
1077 cm-1 and 1028 cm-1, respectively.
The FTIR spectrum of Phospholipon® 90H revealed the characteristic C-H stretching

PT

band of the long-chain fatty acid at ~2918 cm-1 and ~2850 cm-1. The spectrum also exhibited the
carbonyl stretching band in the fatty acid ester at ~1738 cm-1, a P=O stretching band at ~1236

RI

cm-1, a P-O-C Stretching band at 1091 cm-1, and a –N+(CH3)3 stretching band at 970 cm-1.
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In the spectrum of the prepared BN, however, the alkene side-chain stretching band
appeared to have shifted to ~3443cm-1 from 3309cm-1 observed in the spectrum of pure SBE.
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This indicated a possible interaction of the phytoconstituents of the SBE with Phospholipon®
90H. Further, a new absorbance peak was observed at ~1654 cm-1, likely due to the formation of

MA

week bonds between the amide groups present in the phospholipid and the SBE. The band
representing the ketone functional group in the SBE spectrum also appeared to be shifted in the
BN spectrum. Additionally, the band representing the aromatic ring stretching at 1514 cm-1

D

disappeared in the BN spectrum, possibly due to weakening, or shielding by the phospholipid
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molecule. These observations further supported the interactions between the phospholipid and
the SBE, and possible formation of the complex. The SBE components are likely packed in the
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hydrophobic cavity of the phospholipid, and held together by van der Waals forces, and other
hydrophobic interactions (Jena et al., 2014).
Thermal analysis
Thermal analytical techniques such as DSC and TGA are commonly employed to characterize
material properties and analyze the interactions, if any, between the components of a
formulation. Such interactions are usually demonstrated in the form of endothermic/exothermic
peaks that appear, disappear, or change. Measuring changes in enthalpies also provide insights
with respect to these interactions. The DSC thermograms of pure SBE, PM, BN, and pure
Phospholipon® 90H are shown in the figure 7A, 7B, 7C, and 7D, respectively.
The DSC thermogram of pure SBE revealed a broad endothermic peak between 50-100
ºC, possibly due to the dehydration (water evaporation). This thermogram also showed an
endothermic peak around 128 ºC corresponding to the melting of the phytoconstituents. A broad
endothermic peak was observed around 185 ºC and may be attributed to the phase transition of
SBE from a gel to a liquid crystalline state. The thermogram of Phospholipon® 90H showed two
major endothermic peaks at 125 ºC and 182 ºC, respectively. The first peak is likely due to the
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movements of a polar head group of phospholipid, whereas, the second peak could be due to the
phase transition from a gel to a liquid crystalline state, and the carbon-chain in the phospholipid
may have perhaps undergone melting, isomeric or other crystal changes (Semalty et al., 2012). In

PT

the thermogram of the physical mixture (PM) of the SBE and Phospholipon® 90H, two
endothermic peaks were observed at ~86 ºC and ~122 ºC. These two peaks likely corresponded

RI

to the melting of SBE and Phospholipon® 90H, and an interaction between these components
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might have resulted in a shift in their respective melting points. The thermogram of the prepared
BN exhibiteda broad endothermic peak between 50ºC and 85 ºC. This peak appeared to be
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consisting of three partially fused, endothermic peaks at 54 ºC, 63 ºC and 81 ºC, respectively.
This peak also differed significantly compared to the corresponding peaks observed in the

MA

thermograms of pure SBE and pure Phospholipon® 90H. A reduction in the enthalpy and melting
points is shown to reduce the crystallinity and enhance the solubility of the drugs (Singh et al.,
2012). As some of the key peaks observed with SBE and Phospholipon® 90H were observed to

D

disappear from the thermogram of the prepared BN, and the phase transition temperature was
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observed to be lower than that of pure Phospholipon® 90H, these observations indicate the
possible formation of SBE-Phospholipid complex (BN). These findings are in accordance with
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previously reported results. The interactions between the SBE and Phospholipon® 90H can be
attributed to a combination of forces such as hydrogen bonding and/or van der Waals
interactions, and can be considered as an indication of drug amorphization and/or complex
formation, as supported by IR spectroscopy (Khan et al., 2014; Li et al., 2013; Zhang et al.,
2015). The interactions of the SBE with the polar region of Phospholipon® 90H are likely
followed by the intercalation of the SBE within the hydrophobic domains of the phospholipid
molecules. This could result in a sequential decrease in the free hydrophobic domains of the
phospholipid, and the subsequent disappearance of the second endothermic peak of
Phospholipon® 90H, along with a reduction in the phase transition temperature(Singh et al.,
2014). The results obtained from the TGA studies (data not shown), were consistent and
complementary to the DSC results. The weight loss (%) as a function of increasing temperature
was observed to be the slowest for the prepared SBE-Phospholipon® 90H complex in
comparison to that observed with the pure SBE, or the physical mixture of SBE and
Phospholipon® 90H, indicating a relatively higher thermal stability of the prepared BN.
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Powder x-ray diffraction (PXRD)
The x-ray diffraction patterns of pure SBE, Phospholipon® 90H, PM, and BN are shown in the
Figure 8A, 8B, 8C, and 8D, respectively. The diffractogram of the pure SBE exhibited several

PT

sharp peaks at 45°2θ, 40°2θ, 31°2θ, 28°2θ, and 27°2θ. These types of peaks are typical of highly
crystalline materials. Phospholipon® 90H revealed a single, relatively sharp peak at 21°2θ. The
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diffractograms of the physical mixture (PM) showed peaks that appeared to be a combination of
pure SBE and Phospholipon® 90H, while also retaining most of the individual peaks of SBE. In

SC

the diffractogram of the prepared BN, however, only one major peak around 20°2θ was
observed. This peak appeared as a fused peak, and the crystalline peaks observed with pure SBE
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were absent. The results were in agreement with previously reported studies on the phospholipid
complexes of mitomycin-C and curcubitacin B (Cheng et al., 2015; Hou et al., 2013). The

MA

disappearance of the crystalline peaks of pure SBE thus further corroborated the hypothesis of
the formation of SBE-phospholipid complex. It may thus be inferred that SBE is associated in a

D

molecularly dispersed, or in a partially amorphized state within the carrier (Phospholipon® 90H)
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(Semalty et al., 2010).
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Functional evaluation of CN
Apparent solubility
Table 5 shows the estimated apparent solubilitiesof the pure SBE, the physical mixture of SBE
and Phospholipon® 90H (PM), and the prepared Bacopa naturosome (BN). The lipophilic nature
of the SBE was evident from its poor aqueous solubility (~12µg/mL), and a comparatively
higher solubility in n-octanol (~160 µg/mL). The aqueous solubility of SBE in the physical
mixture (PM) was not found to be significantly different compared to that of pure SBE (~18
µg/mL). The aqueous solubility of the prepared SBE-Phospholipon® 90H complex (BN)
however, was found to be significantly higher compared to either that of the pure SBE, or the
SBE in the physical mixture (PM). BN showed over 20-fold enhancement in the aqueous
solubility compared to that of pure SBE, and over 13-fold enhancement compared to that of the
SBE in the physical mixture. Partial amorphization (reduced molecular crystallinity) of the drug,
and the overall amphiphilic nature of the BNmay likely explain this increase in the solubility of
the prepared complex(Maiti et al., 2007; Xia et al., 2013). The Phospholipon® 90H molecule and
the hydrophobic moiety of SBE may form a quasi-stable bonding; and the phospholipid molecule
may possibly enwrap the non-polar groups in the SBE, thus enhancing its aqueous solubility
(Kidd, 2009; Tan et al., 2012).
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In-vitro drug release (dissolution)
The Figure 9 shows the dissolution profiles of the pure SBE, the physical mixture of SBE and
Phospholipon® 90H (PM), and the prepared Bacopa naturosome (BN) in the phosphate buffer

PT

(pH 6.8). The pure SBE exhibited the slowest rate of dissolution, i.e. only about 42% w/w SBE
was released at the end of 11-hour dissolution period. Similarly, the dissolution rate of SBE in
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the PM also appeared to be slower, and not significantly different from that of pure SBE, i.e.
~47% w/w SBE was released at the end of 11 hours. The dissolution profile of the BN, however,
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showed a significantly higher rate of SBE release from the prepared SBE-Phospholipon® 90H
complex (BN). At the end of 11 hours, over 97% w/w SBE was released from the BN, following
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a near zero-order release. Crystal morphology and the wettability of solids are known to
influence the dissolution rate; and the partially amorphized state of the SBE in the prepared BN,
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and subsequent improvement in the aqueous solubility may explain the improved dissolution of
the SBE in BN (Freag et al., 2013; Semalty et al., 2010). The relatively higher amorphous nature
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of the prepared complex may have had a positive impact on the cumulative release of the SBE.
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Dissolution efficiency (DE)
The dissolution efficiencies calculated from the in-vitro dissolution studies in phosphate buffer
(pH-6.8), for the pure SBE, the physical mixture of SBE and Phospholipon® 90H (PM), and the
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prepared SBE- Phospholipon® 90H complex (BN) are shown in Table 6. At the end of 11 hours,
pure SBE exhibited a dissolution efficiency of ~22%. The dissolution efficiency of SBE in the
physical mixture showed a marginal, but a statistically significant (p <0.01) increase, compared
to the pure SBE. This increase could be attributed to the amphiphilic nature of the phospholipids,
and their solubilizing characteristics. The prepared SBE- Phospholipon® 90H complex (BN)
however, revealed a significant (p <0.001) improvement in the dissolution efficiency compared
to that of either pure SBE, or the SBE in the physical mixture. At the end of 11 hours, over 2.5fold increase in the DE was seen for the prepared BN. This observed increase in the release of
SBE from BN can be attributed to the partial amorphization of SBE in the prepared complex, and
subsequent improvement in the aqueous solubility of SBE.
Ex-vivo permeability
Figure 10 shows the results of the three-hour, ex-vivo permeability analysis of the pure SBE, the
physical mixture of SBE and Phospholipon® 90H (PM), and the prepared SBE- Phospholipon®
90H complex (BN), as performed with the everted intestine method. The relative permeabilities
of the tested samples across the everted intestinal membrane appeared to follow a similar pattern
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to that observed with the in-vitro dissolution studies. Among the samples evaluated, the pure
SBE exhibited the slowest rate and extent of permeation, i.e. only about 21% w/w SBE
permeation was observed at the end of three hours. The permeation of SBE from the physical
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mixture was not found to be significantly different from that observed with pure SBE. The rate
and extent of SBE permeation from the prepared SBE- Phospholipon® 90H complex (BN) was
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found to be significantly higher compared to that observed with either pure SBE, or the physical
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mixture. At the end of three hours,over 90% w/w of SBE was observed to be permeated through
the intestinal membrane. The amphiphilic nature of the phospholipids may lend itself for them to
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function as surfactants, assisting the drug to traverse across the membrane. Considering the
observed increase in the apparent aqueous solubility of SBE, an increase in the rate and extent of

MA

SBE release, and the improved permeability of SBE from the prepared BN, complex formation
of drugs, with phospholipids as carriers can be employed as a potential alternative strategy to
enhance the delivery of SBE or other similar phytoconstituents.
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Preliminary pharmacological evaluation
The preliminary antidepressant-like activity of the prepared SBE-Phospholipon® 90H complex
(BN) was analyzed using established behavioral models (Porsolt et al., 1977; Steru et al., 1985).
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The results of the Tail Suspension Test and Forced Swim Test are shown in the Figure 11(A) and
Figure 11(B), respectively. As shown in the Figure 11 (A), a five-day treatment of mice with
imipramine (10 mg/kg), pure SBE (40 mg/kg), or the prepared SBE-Phospholipon® 90H
complex resulted in a significant decrease in the duration of immobility in the Tail Suspension
Test. The observed decrease in the immobility was found to be 44.8%, 23.4%, and 46.9% for
imipramine, pure SBE, and the SBE-Phospholipon® 90H complex, respectively [one-way
ANOVA, F (3, 23) = 17.08, p <0.0001]. The post hoc Bonferroni’s multiple comparison test
revealed that the prepared SBE-Phospholipon® 90H complex (BN) elicited antidepressant-like
effects similar to those observed with the known antidepressant, imipramine (p <0.05).
Interestingly, these effects of the prepared BN were also observed to be significantly better
compared to pure SBE (p <0.05).
The antidepressant-like effects of pure SBE and the prepared BN were also confirmed
using Forced Swim Test. As shown in the Figure 11 (A), a five-day treatment of mice with
imipramine (10 mg/kg, i.p.), pure SBE (40 mg/kg), or the prepared SBE-Phospholipon® 90H
complex resulted in a significant decrease in the duration of immobility in this test. The
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immobility was found to be decreased by 43.9%, 22.8% and 45.6%, for imipramine, pure SBE,
and the SBE-Phospholipon® 90H complex, respectively[F(3, 23) = 16.53, p < 0.0001]. The post
hoc Bonferroni’s multiple comparison test revealed that the prepared SBE-Phospholipon® 90H
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complex (BN) elicited antidepressant-like effects similar to those observed with the known
antidepressant, imipramine (p <0.05). Interestingly, these effects of the prepared BN were also
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observed to be significantly better compared to pure SBE (p <0.05).The improved

SC

pharmacological activity of the prepared complex observed with both tests can be attributed to
the increased solubility, permeability, and possibly overall bioavailability of SBE from the
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complex.

The duration of immobility measured in the above behavioral tests in mice have been

MA

known to reflect a state of ‘behavioral despair and variants’ or ‘failure to adapt to stress’ (Willner
and Muscat, 1991). A functional deficiency of the cerebral monoaminergic transmitters such as
norepinephrine, 5-hydroxy tryptamine, and/or dopamine, located at the synapses isthought to be
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the predominant contributor of depression (Schildkraut, 1965). The antidepressant-like activity
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of Bacopa extract is reported to be due to its adaptogenic effects via normalization of various
stress parameters and monoaminergic levels, resulting in the restoration of normal
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monoaminergic neurotransmitters (Rai et al., 2003). Bacopasides, which are the major
constituents of Bacopa, are also reported to exhibit antidepressant effects by improving the vital
neurotransmitter activities (Chatterjee et al., 2010). Additionally, the neurochemical studies
following the behavioral despair tests have previously revealed an improved brain antioxidant
activity (Liu et al., 2013; Mannan et al., 2015). Thus, the observed antidepressant effects of
Bacopa extract in the present study might be related to both, the antioxidant activation and the
noradrenergic neurotransmitter activation.
Conclusions
The feasibility of enhancing the aqueous solubility of the SBE was attempted via preparing its
complex with phospholipids (Bacopa Naturosome, BN) in the current study. The formulation and
process variables were optimized using a central composite design. The physicochemical and
functional characteristics of the prepared BN were evaluated, and compared to that of pure SBE.
The successful formation of a vesicular SBE-Phospholipon® 90H complex was ascertained via
FTIR, DSC, PXRD, photomicroscopy, and the SEM studies. The solubility analysis, the in-vitro
drug release studies (dissolution), and the permeability analysis across the everted rat intestine
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(ex-vivo) indicated that, the aqueous solubility, the drug release, and the membrane permeation
of the SBE from the prepared BN showed a significant improvement as a result of complex

PT

formation.
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Figure 1: Pareto diagrams for the estimation of effects. The effects presenting probability values
higher than 0.05 are not considered as statistically significant.
Figure 2: The response surface plots and the contour plots of entrapment efficiency (Y, %) as a

PT

function of the ratio of Phospholipon® 90H and SBE (X1, w:w), the reaction temperature (X2,
°C), and the reaction time (X3, h).
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Figure 3: The photo-microscopic images of (A) pure SBE, and (B) the SBE- Phospholipon®

SC

90H complex at a magnification of 20X.

Figure 4: The SEM photomicrographs of SBE- Phospholipon® 90H complex.

NU

Figure 5: (A) Particle size distribution, and (B) Zeta potential profiles of the SBEPhospholipon® 90H complex

Figure 6: The FTIR spectra of (A) pure SBE, (B) Phospholipon® 90H, (C) the physical mixture

MA

(1:1) of SBE and Phospholipon® 90H, and (D) SBE- Phospholipon® 90H complex.
Figure 7: DSC thermograms of (A) pure SBE, (B) Phospholipon® 90H, (C) the physical mixture

D

(1:1) of SBE and Phospholipon® 90H, and (D) SBE- Phospholipon® 90H complex.
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Figure 8: The X-ray diffractograms of (A) pure SBE, (B) Phospholipon® 90H, (C) the physical
mixture (1:1) of SBE and Phospholipon® 90H, and (D) SBE- Phospholipon® 90H complex.
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Figure 9: The in-vitro dissolution profiles of pure SBE, the physical mixture (1:1) of SBE and
Phospholipon® 90H, and the SBE- Phospholipon® 90H complex.
Figure 10: The ex-vivo permeability profiles of pure SBE, the physical mixture (1:1) of SBE and
Phospholipon® 90H, and the SBE- Phospholipon® 90H complex.
Figure 11: Tail Suspension Test (A) and Forced Swim Test (B) in mice. Animals were treated with
®
saline (control), imipramine (10 mg/kg, i.p.), pure SBE (40 mg/kg), or the SBE- Phospholipon 90H
complex (equivalent to SBE 40 mg/kg). Data expressed as mean ± SEM. *p < 0.05, **p < 0.001 vs
control; ***p < 0.05 vs pure SBE.
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Table 1: Coded levels and “Real” values for each factor under study.
Variables
Levels
-1.7 -1
0
+1 +1.7
Independent
Real values
Phospholipid : drug ratio (X1, w:w) 0.5 1.0 1.8 2.5 3.0
Reaction temperature (X2, °C)
40.0 44.0 50.0 56.0 60.0
Reaction time (X3, h)
1.0 1.4 2.0 2.6 3.0
Dependent
Entrapment efficiency (Y, % w/w)
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Table 2: Central composite design formulation batches with respective entrapment efficiencies.
Batches X1
X2
X3 Entrapment efficiency* (%, w/w)
F1
-1
+1
+1
79.2 ± 0.9
F2
-1
-1
+1
80.3 ± 1.3
F3
+1.7
0
0
87.7 ± 1.0
F4
+1
-1
+1
85.3 ± 1.0
F5
0
0
-1.7
63.2 ± 1.1
F6
-1.7
0
0
58.3 ± 1.2
F7
0
0
+1.7
86.9 ± 1.3
F8
+1
+1
+1
87.2 ± 1.2
F9
0
-1.7
0
72.7 ± 0.9
F10
-1
-1
-1
53.1 ± 1.3
F11
-1
+1
-1
73.1 ± 1.1
F12
0
+1.7
0
86.5 ± 1.1
F13
+1
+1
-1
88.2 ± 1.0
F14
+1
-1
-1
83.3 ± 1.3
F15- F20
0
0
0
85.8 ± 1.0
* Values represent mean ± standard deviation (n=3)
Table 3: ANOVA of the Quadratic Model.
Source
Sum of squares Degrees of freedom Mean square Fcritical p value
Regression
1976.8
9
219.7
19.4
0.001
Residual
113.4
10
11.3
Total
2090.2
19
Table 4: Comparison of the observed and predicted entrapment efficiency (%) values of SBEPhospholipon® 90H complex (BN), prepared under predicted optimum conditions
Response Variable
Predicted Value Observed value* Bias (%)
Entrapment efficiency (%)
85.7
87.1 ± 1.2
-1.7
*: Values represent mean ± standard deviation (n=3)
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Table 5: Solubility profiles of pure SBE, the physical mixture (1:1) of SBE and Phospholipon ®
90H (PM), and the SBE- Phospholipon® 90H complex (BN).
Sample
Aqueous solubility (µg/ml)* n-Octanol solubility (µg/ml)*
Pure SBE
11.9 ± 0.7
160.4 ± 1.8
PM
18.3 ± 0.4
173.2 ± 1.1
BN
249.4 ± 2.1
198.2 ± 2.1
*: Data expressed as mean values and standard deviations (±SD); n = 3
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Table 6: Calculated dissolution efficiencies of pure SBE, the physical mixture (1:1) of SBE and
Phospholipon® 90H (PM), and the SBE- Phospholipon® 90H complex (BN) in phosphate buffer
(pH-6.8).
Time (h)
Dissolution efficiency (DE) (%)
Pure SBE
PM
BN
11
22.0 ± 1.1 24.2 ± 1.0* 56.4 ± 1.7**
All values are mean ± SD (n = 3). The level of significance is p < 0.05, * implies p ≤ 0.01, **
implies p ≤ 0.001 as compared to pure SBE.
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